$UPB News

Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026

HC Wainwright & Co. Reiterates Buy on Upstream Bio, Maintains $36 Price Target

Upstream Bio on Track to Begin Two Phase 3 Verekitug Trials in Q1 2027

JP Morgan Maintains Neutral on Upstream Bio, Raises Price Target to $9

Truist Securities Maintains Buy on Upstream Bio, Lowers Price Target to $25

Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates

Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress

Upstream Bio Q2 EPS $(0.73) Beats $(0.76) Estimate, Sales $773.000K Beat $430.714K Estimate

Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?

Is Upstream Bio, Inc. (UPB) a Rising Biotech Opportunity After New Analyst Coverage?

Reported Sunday, Upstream Bio Presents Phase 2 VIBRANT Data Showing 79% Of Verekitug-Treated CRSwNP Patients Achieved Clinically Meaningful Nasal Polyp Score Improvements Versus 24% On Placebo

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026

JP Morgan Downgrades Upstream Bio to Neutral, Lowers Price Target to $8

Upstream Bio, Inc. (UPB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026

Upstream Bio to Present New Verekitug Data at EAACI 2026, Phase 2 Nasal Polyps Analysis Gets EAACI Oral Presentation

Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

HC Wainwright & Co. Initiates Coverage On Upstream Bio with Buy Rating, Announces Price Target of $36

Upstream Bio: The Reset Is The Opportunity, Initiating At Buy

Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference